摘要
通过角膜移植更换混浊或病变的角膜,是帮助角膜盲患者恢复视力的有效措施,但植片排斥反应的发生是导致角膜移植手术远期失败的主要原因,如何减少因植片排斥引起的再次致盲是角膜病研究的重点。本文分析了我国角膜移植免疫研究存在的问题:(1)没有建立标准的抗排斥治疗方案;(2)缺乏安全、有效的抗排斥反应治疗药物;(3)忽视围手术期的并发症处理;(4)角膜移植免疫基础研究薄弱。针对上述问题产生的原因,提出了相应的处理措施和建议,以增强角膜病专科医生对角膜移植免疫临床和基础研究的重视,促进我国角膜盲的防治工作取得更大的发展。
Corneal transplantation is a major therapeutic method to recover the patient＇s sight from corneal blindness, however, the immune rejection is still the major impact factor for graft failure. How to prevent the blindness caused by donor rejection is important in corneal study. The principal problems in China are analyzed in this paper： （ 1 ） standard treatment of graft rejection not to be established; （2） lack of anti-rejection drugs; （3） ignorance of the complication management after corneal transplantation; （4） less basic research to corneal transplantation immunology. The update immune refection theory and the means of reducing the rejection of the corneal graft, and the methods to reduce the risk of blindness due to immune rejection would be focused on this paper.
出处
《眼科》
CAS
2009年第6期370-373,共4页
Ophthalmology in China
关键词
角膜移植
植片排斥
角膜移植免疫
corneal transplantation
graft rejection
corneal transplantation immunology
